Cumberland Pharmaceuticals, Inc. (CPIX) Reports Q1 EPS of $0.02

Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) reported Q1 EPS of $0.02, versus $0.05 reported last year. Revenue for the quarter came in at $8.09 million, versus $10.26 million reported last year.

As of March 31, 2014, Cumberland had $52.6 million in cash and marketable securities, with approximately $39.0 million in cash and equivalents and $13.5 million in marketable securities. Total assets at March 31, 2014, were $91.1 million and the Company had no debt at the end of the first quarter.

"We are very optimistic about the opportunities that Vaprisol and Omeclamox-Pak will offer Cumberland. We continue to build a diversified product portfolio while deploying our resources to sustain long-term growth," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "The joint investment with Gloria will allow us to continue to both accelerate the development of existing CET projects and pursue new product candidates."

For earnings history and earnings-related data on Cumberland Pharmaceuticals, Inc. (CPIX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI